She maintains a longstanding interest in the studies of children and adolescents with kidney disease, particularly their risk factors and consequences, including pediatric hypertension. As Principal Investigator of CKiD, she directs a multidisciplinary team for one of the largest multicenter, prospective cohort studies of children with CKD to better identify risk factors for CKD progression, neurocognitive deficits and CVD. Dr Furth is also a recipient of an National Institute of Diabetes and Digestive and Kidney Diseases Investigator Award in Clinical Research to mentor fellows and junior faculty on the evaluation of hypertension and risk of kidney dysfunction using national pediatric data. In addition to being a peer reviewer for 20 academic journals, Dr Furth has authored over 100 publications and served as a thesis advisor to more than 30 students. As an acknowledgment for her contribution, Dr Furth was awarded Pediatric Leaders for the 21st Century by the American Society of Pediatric Nephrology and American Academy of Pediatrics and is currently President of the Society for Pediatric Research. Dr Furth reported no relevant financial relationships Hallvard Holdaas, MD, PhD, is senior consultant in Nephrology at Department of Transplant Medicine, Oslo University Hospital, Rikshospitalet, Norway, where he also received his training in transplant medicine. His primary research interests are immunosuppression, dyslipidemia, and CVD in renal transplant recipients. He was the principal investigator in the ALERT trial (fluvastatin) and co- investigator in the AURORA and SHARP trials. Dr Holdaas is a member of numerous professional organizations including American Society of Nephrology, American Society of Transplantation, European Dialysis and biographic and disclosure information Transplant Association and European Society for Organ Transplantation. He has published more than 170 original articles, reviews and book chapters in the fields of nephrology, dialysis and transplantation. 